Hot or Not, Stock Market Edition: 06/04/2026

Recently, we did a little audit of Nancy Pelosi’s 2026 stock picks … and we found them lacking. (True story.) However, we did unearth 2 hot stocks that follow Pelosi’s playbook that have more solid fundamentals and near-term prospects. Here’s our review. 

A note from our sponsors...

P.S. Your Monday Night Market Edge… Every Monday at 7pm ET, our Editor-in-Chief Steve Reitmeister reveals the stocks, sectors, and setups he’s targeting personally — including his single highest-conviction Stock of the Week that he only shares live. Gain complimentary access here.

🔥 HOT: Acadian Asset Management (AAMI) isn’t a Pelosi pick, but we unearthed it following her approach with AB, one of the “not hot” stocks on this list. The stock is benefiting from the growing demand for AI-powered and quantitative investing strategies. Why? Because as institutional investors shift toward systematic and data-driven portfolio management, Acadian is well-positioned to capitalize without carrying the extreme valuations seen in many AI stocks.

The company also brings solid fundamentals to the table. Acadian runs a profitable asset management business with recurring fee revenue and strong cash generation. AAMI earns an A Zen Rating, equivalent to a Strong Buy recommendation, buoyed by strong Component Grades for Financials, Growth, Momentum, and Sentiment — a potent combo. Bottom line? As quant-driven investing continues gaining traction, Acadian offers exposure to the trend with a much stronger financial profile than many speculative AI names.  

🥶 NOT: Here’s a Pelosi pick that hasn’t gone according to plan. Sure, AllianceBernstein (AB) is only down about 5% since she bought, and it may look attractive at first glance because of its dividend yield. But there are serious headwinds to consider. Over the last several years, earnings growth has been inconsistent, and the stock has significantly lagged many higher-quality financial names tied to stronger secular trends like AI infrastructure, capital markets, or alternative assets. Asset managers also tend to struggle when markets become volatile because lower asset prices directly pressure assets under management and fee revenue. WallStreetZen’s model reflects some of those concerns. AB earns an overall C (Hold) rating, and scores weaker on Growth and Momentum relative to stronger-rated financial stocks. This also isn’t a business with a major catalyst changing the narrative right now. The company remains profitable and stable, but stability alone doesn’t usually drive major stock outperformance. Our take? Move past this one and focus on tickers like AAMI, our pick on this list.

🔥 HOT:  Veracyte (VCYT) is not a Pelosi pick, but we sourced it as a higher-quality alternative to one of her confirmed investments, Tempus AI (featured below). Whereas Tempus AI lost $300 million, Veracyte made $88 million in profit over the past 12 months. They’re also doing it efficiently. They managed to pull off earnings growth of almost 160%, off of a 17% increase in revenue. The company specializes in genomic diagnostics and precision medicine tools that help doctors make more accurate treatment decisions, an area that stands to benefit enormously from the growing role of AI in healthcare. WallStreetZen gives VCYT an overall A (Strong Buy) rating, with strong marks for Growth, Financials, and Sentiment. And did we mention that analysts forecast over 80% potential upside for the stock in the coming year? When you factor in the fact that the broader precision diagnostics trend still looks to be in the early innings, it’s a compelling watch. This is the type of stock that could quietly compound higher if execution continues and institutional interest keeps building. 

🥶 NOT: Confirmed Pelosi investment Tempus AI (TEM) is the kind of “hot” AI stock Wall Street loves — combining artificial intelligence, healthcare, and precision medicine. That appeal even drew in former House Speaker Nancy Pelosi earlier this year. Investors are betting the company can use AI and genomic data to reshape disease detection and treatment. But the stock has already been extremely volatile. Since Pelosi’s disclosed purchase, shares have dropped about 25%, highlighting how speculative the name still is. Tempus continues posting losses while trading at a valuation that assumes major long-term success. Revenue growth is strong, but profitability remains far away. The Zen Ratings sees right through the hype, assigning TEM a D rating, which amounts to a Sell recommendation. The Component Grades that shape the overall rating are particularly weak in 4 key areas: Financials, Momentum, Safety, and from our proprietary AI factor that sifts through mountains of data to find stocks best positioned to outperform. Bottom line? Tempus AI has an exciting story, but the stock still looks too speculative for most investors right now.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.